

## Rifaximin effective for repeat treatment of IBS with diarrhea

27 December 2016



but not for stool consistency (P = 0.42). There were also significant improvements for prevention of recurrence, durable response, and <u>bowel</u> <u>movement</u> urgency. The groups had similar adverse event rates.

"In a phase 3 study of patients with relapsing symptoms of IBS-D, repeat rifaximin treatment was efficacious and well tolerated," the authors write.

Several authors disclosed financial ties to Salix Pharmaceuticals, which manufactures rifaximin and funded the study.

More information: Full Text

Copyright © 2016 HealthDay. All rights reserved.

(HealthDay)—Repeat treatment with the nonsystemic antibiotic rifaximin is effective in patients with relapsing symptoms of diarrhea-predominant irritable bowel syndrome (IBS-D), according to a study published in the December issue of *Gastroenterology*.

Anthony Lembo, M.D., from the Beth Israel Deaconess Medical Center in Boston, and colleagues conducted a multicenter, phase 3, randomized, placebo-controlled trial to evaluate the safety and efficacy of repeat treatment with the nonsystemic antibiotic rifaximin (550 mg three times daily for two weeks) among 636 adults with IBS-D, mean abdominal pain and bloating scores of 3 or more, and loose stool (February 2012 through June 2014).

The researchers found that the percentage of responders was significantly greater with rifaximin than placebo (P = 0.03). For abdominal pain, the percentage of responders (P = 0.018) was significantly greater with rifaximin versus placebo,



APA citation: Rifaximin effective for repeat treatment of IBS with diarrhea (2016, December 27) retrieved 7 June 2021 from <a href="https://medicalxpress.com/news/2016-12-rifaximin-effective-treatment-ibs-diarrhea.html">https://medicalxpress.com/news/2016-12-rifaximin-effective-treatment-ibs-diarrhea.html</a>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.